Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow iSpecimen Inc.

Get SEC filing alerts via email and in your feed for iSpecimen Inc.

ISPC

iSpecimen Inc.

About iSpecimen Inc.

iSpecimen Inc. operates a technology-driven marketplace connecting life science researchers with human biospecimens and associated data from healthcare providers worldwide. Its platform streamlines biospecimen procurement, offering access to diverse specimen types and extensive healthcare data, supporting research in diagnostics, therapeutics, and precision medicine. The company facilitates compliant, efficient transactions between researchers and biospecimen providers, enabling accelerated medical discovery and development.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from iSpecimen Inc.

1
1
iSpecimen Inc. iSpecimen Inc. Reports 85% Revenue Decline and Increased Net Loss in Latest 10-Q Filing

Via official filing (AI summary) | 17 days ago | 0 comments

2
1
iSpecimen Inc. iSpecimen Reports 79% Revenue Decline and $10.49 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
iSpecimen Inc. iSpecimen Reports 96% Revenue Decline and Increased Net Loss in Latest Quarter

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
iSpecimen Inc. iSpecimen Inc. Reports 75% Revenue Decline and $1M Net Loss in Latest Quarter

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
iSpecimen Inc. iSpecimen Inc. Reports 54% Revenue Decline in Q1 2025 Amid Cost-Cutting Measures

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
iSpecimen Inc. iSpecimen Inc. Reports $12.5 Million Net Loss and Revenue Decline for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
iSpecimen Inc. iSpecimen Reports Mixed Q3 2024 Financial Results, Sees Improvement in Net Loss and Operating Expenses

Via official filing (AI summary) | over 1 year ago | 0 comments